Dendreon Corp (DNDNQ) 0.0930 $DNDNQ
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Wall Street Breakfast: Apple's Market Cap Closes Above $700B
Wall Street Breakfast - at Seeking Alpha - Wed Feb 11, 5:30AM CST
TSLA: 203.77 (+0.89), VRX: 167.00 (-0.50), AMX: 21.97 (+0.27), HAL: 44.19 (+1.42), PBR: 6.98 (+0.44), ANTM: 141.05 (-0.95), FSLR: 48.84 (-0.58), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), ARMH: 49.92 (-0.49), MSFT: 43.87 (+0.78), AAPL: 127.08 (+0.62), INTU: 90.25 (+0.86)
Reuters: Valeant close to Dendreon purchase
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 1:49AM CST
VRX: 167.00 (-0.50)
Dendreon Announces Expiration of Bid Deadline in Connection with Agreement to Sell Substantially All Assets to Valeant
Business Wire - Tue Feb 10, 4:15PM CST
--Dendreon and Valeant to Seek Court Approval of Sale on February 20, 2015
VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)
PR Newswire - Thu Feb 05, 9:30AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that yesterday it entered into an amended and restated "stalking horse" asset purchase agreement to acquire the world-wide rights to Dendreon's PROVENGE® (sipuleucel-T) product and certain other assets of Dendreon Corporation ("Dendreon"
. In response to competing bids, Valeant has raised its offer to $400 million in cash for the assets, which realized combined revenues of approximately $300 million in 2014.
VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
Is Valeant Making A Mistake By Purchasing Rights To Provenge?
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 5:22PM CST
VRX: 167.00 (-0.50)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
Regeneron Shows Biotech Investors Have Left Their Wildcatting Days
Dana Blankenhorn - at Seeking Alpha - Fri Jan 30, 11:12AM CST
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), XOM: 93.37 (+1.00), AMGN: 153.48 (+0.30), REGN: 402.40 (+0.66), SLB: 88.38 (+2.42), CELG: 115.88 (+0.16)
Wall Street Breakfast: Amazon Shares Surge After Profit Beat
Wall Street Breakfast - at Seeking Alpha - Fri Jan 30, 5:31AM CST
AMZN: 381.83 (+4.66), VRX: 167.00 (-0.50), SHAK: 40.69 (+0.04), OSTK: 22.45 (-0.13), CCRN: 11.13 (-0.28), LPG: 12.67 (+0.11), GOOG: 549.01 (+6.08), CVC: 20.60 (+0.32), PBR: 6.98 (+0.44), V: 269.63 (-1.28), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), TRP: 45.94 (-0.81), XCO: 2.52 (+0.20), GOOGL: 551.16 (+5.15), HMC: 32.87 (+0.14), VZ: 49.31 (-0.21)
Dendreon's Asset Rummage Sale Completes the Circle of Life
at The Street - Fri Jan 30, 5:01AM CST
Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.
VRX: 167.00 (-0.50), JUNO: 40.52 (+0.18)
Valeant to purchase Dendreon's Provenge
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 2:47AM CST
VRX: 167.00 (-0.50)
Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)
PR Newswire - Thu Jan 29, 8:00PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into a "stalking horse" asset purchase agreement to acquire certain assets of Dendreon Corporation ("Dendreon" for $296 million in cash.
VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
M2 - Wed Jan 21, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/qxt9lq/global_prostate) has announced the addition of the "Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" report to their offering. Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years. Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients. Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights: - Introduction to Prostate Cancer Vaccine - Mechanism of Prostate Cancer Vaccine - Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase - Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines - Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines - Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation) Key Topics Covered: 1. Introduction to Prostate Cancer Vaccine 2. Mechanism of Prostate Cancer Vaccine 3. Global Prostate Cancer Vaccine Market Dynamics 4. Global Prostate Cancer Vaccine Market Outlook 5. Global Prostate Cancer Vaccine Market Future Prospects 6. Personalized Cancer Vaccine Market Opportunities 7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase 8. Marketed Prostate Cancer Vaccines by Company & Country 9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials 10. Competitive Landscape - Adamis Pharmaceuticals - Aduro BioTech - Bellicum Pharmaceuticals - CytoVac - Dendreon Corporation - Generex Biotechnology Corporation - Immunovaccine - Oncbiomune - Progenics - Sotio For more information visit http://www.researchandmarkets.com/research/qx...l_prostate
BLCM: 20.00 (-0.81), ADMP: 6.50 (-0.01)
Dendreon Announces Strong Commercial Start to 2015
Business Wire - Wed Jan 14, 7:30AM CST
January 14, 2015 - Dendreon Corporation today announced that the company grew sales in four quarters successively, exceeded its revenue target for the first time ever, and achieved cash-flow break even in the fourth quarter (adjusted for non-recurring items), starting 2015 on a strong footing. In addition, the first commercial European patient initiated treatment with PROVENGE(R) (sipuleucel-T) in Germany - the first country outside of the U.S. to offer the novel immunotherapy for advanced prostate cancer since receiving marketing authorization in the European Union (EU) in 2013.
How I Earned 17% Compound Annual Return For 6 Years
Michael Hooper - at Seeking Alpha - Wed Dec 31, 6:51AM CST
RAI: 71.86 (-1.23), JNJ: 99.62 (+1.18), CHD: 84.03 (+0.67), SAM: 303.26 (-0.97), AAPL: 127.08 (+0.62), UNP: 122.60 (-1.23), CL: 70.08 (+0.23)
Delisting of Securities of GT Advanced Technologies, Inc., Dendreon Corporation, MabVax Therapeutics Holdings, Inc., and Tri-Tech Holding Inc. From The Nasdaq Stock Market
GlobeNewswire - Wed Dec 10, 3:05PM CST
The Nasdaq Stock Market announced today that it will delist the common stock of GT Advanced Technologies, Inc. GT Advanced Technologies, Inc.'s stock was suspended on October 16, 2014 and has not traded on Nasdaq since that time.
NDAQ: 49.48 (-0.27)
Could This Company Follow in Dendreon's Footsteps?
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 10:11AM CST
When it comes to the investing world, the ultimate compliment you or your company can get is being compared to the likes of visionaries like Warren Buffett or iconic companies likes Apple or Coca-Cola . If there's an antithesis to the iconic...
KO: 41.99 (-0.18), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02), AAPL: 127.08 (+0.62)
A New Combined Approach to Cancer Immunotherapy is Needed
ACCESSWIRE - Mon Dec 01, 11:35AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / With the recent bankruptcy of Dendreon Corporation (NASDAQ
NDN) due to disappointing sales of its flagship Provenge prostate cancer vaccine, the future of cancer immunotherapy just got a bit cloudier. While Provenge itself will survive, Dendreon may end up going private in a debt restructuring deal.
DNDN: 0.13 (-0.02), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Wall Street Breakfast: Apple's Market Cap Closes Above $700B
Wall Street Breakfast - at Seeking Alpha - Wed Feb 11, 5:30AM CST
TSLA: 203.77 (+0.89), VRX: 167.00 (-0.50), AMX: 21.97 (+0.27), HAL: 44.19 (+1.42), PBR: 6.98 (+0.44), ANTM: 141.05 (-0.95), FSLR: 48.84 (-0.58), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), ARMH: 49.92 (-0.49), MSFT: 43.87 (+0.78), AAPL: 127.08 (+0.62), INTU: 90.25 (+0.86)
Reuters: Valeant close to Dendreon purchase
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 1:49AM CST
VRX: 167.00 (-0.50)
Dendreon Announces Expiration of Bid Deadline in Connection with Agreement to Sell Substantially All Assets to Valeant
Business Wire - Tue Feb 10, 4:15PM CST
--Dendreon and Valeant to Seek Court Approval of Sale on February 20, 2015
VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)
PR Newswire - Thu Feb 05, 9:30AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that yesterday it entered into an amended and restated "stalking horse" asset purchase agreement to acquire the world-wide rights to Dendreon's PROVENGE® (sipuleucel-T) product and certain other assets of Dendreon Corporation ("Dendreon"
. In response to competing bids, Valeant has raised its offer to $400 million in cash for the assets, which realized combined revenues of approximately $300 million in 2014. VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
Is Valeant Making A Mistake By Purchasing Rights To Provenge?
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 5:22PM CST
VRX: 167.00 (-0.50)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
Regeneron Shows Biotech Investors Have Left Their Wildcatting Days
Dana Blankenhorn - at Seeking Alpha - Fri Jan 30, 11:12AM CST
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), XOM: 93.37 (+1.00), AMGN: 153.48 (+0.30), REGN: 402.40 (+0.66), SLB: 88.38 (+2.42), CELG: 115.88 (+0.16)
Wall Street Breakfast: Amazon Shares Surge After Profit Beat
Wall Street Breakfast - at Seeking Alpha - Fri Jan 30, 5:31AM CST
AMZN: 381.83 (+4.66), VRX: 167.00 (-0.50), SHAK: 40.69 (+0.04), OSTK: 22.45 (-0.13), CCRN: 11.13 (-0.28), LPG: 12.67 (+0.11), GOOG: 549.01 (+6.08), CVC: 20.60 (+0.32), PBR: 6.98 (+0.44), V: 269.63 (-1.28), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), TRP: 45.94 (-0.81), XCO: 2.52 (+0.20), GOOGL: 551.16 (+5.15), HMC: 32.87 (+0.14), VZ: 49.31 (-0.21)
Dendreon's Asset Rummage Sale Completes the Circle of Life
at The Street - Fri Jan 30, 5:01AM CST
Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.
VRX: 167.00 (-0.50), JUNO: 40.52 (+0.18)
Valeant to purchase Dendreon's Provenge
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 2:47AM CST
VRX: 167.00 (-0.50)
Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)
PR Newswire - Thu Jan 29, 8:00PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into a "stalking horse" asset purchase agreement to acquire certain assets of Dendreon Corporation ("Dendreon"
for $296 million in cash. VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
M2 - Wed Jan 21, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/qxt9lq/global_prostate) has announced the addition of the "Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" report to their offering. Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years. Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients. Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights: - Introduction to Prostate Cancer Vaccine - Mechanism of Prostate Cancer Vaccine - Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase - Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines - Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines - Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation) Key Topics Covered: 1. Introduction to Prostate Cancer Vaccine 2. Mechanism of Prostate Cancer Vaccine 3. Global Prostate Cancer Vaccine Market Dynamics 4. Global Prostate Cancer Vaccine Market Outlook 5. Global Prostate Cancer Vaccine Market Future Prospects 6. Personalized Cancer Vaccine Market Opportunities 7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase 8. Marketed Prostate Cancer Vaccines by Company & Country 9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials 10. Competitive Landscape - Adamis Pharmaceuticals - Aduro BioTech - Bellicum Pharmaceuticals - CytoVac - Dendreon Corporation - Generex Biotechnology Corporation - Immunovaccine - Oncbiomune - Progenics - Sotio For more information visit http://www.researchandmarkets.com/research/qx...l_prostate
BLCM: 20.00 (-0.81), ADMP: 6.50 (-0.01)
Dendreon Announces Strong Commercial Start to 2015
Business Wire - Wed Jan 14, 7:30AM CST
January 14, 2015 - Dendreon Corporation today announced that the company grew sales in four quarters successively, exceeded its revenue target for the first time ever, and achieved cash-flow break even in the fourth quarter (adjusted for non-recurring items), starting 2015 on a strong footing. In addition, the first commercial European patient initiated treatment with PROVENGE(R) (sipuleucel-T) in Germany - the first country outside of the U.S. to offer the novel immunotherapy for advanced prostate cancer since receiving marketing authorization in the European Union (EU) in 2013.
How I Earned 17% Compound Annual Return For 6 Years
Michael Hooper - at Seeking Alpha - Wed Dec 31, 6:51AM CST
RAI: 71.86 (-1.23), JNJ: 99.62 (+1.18), CHD: 84.03 (+0.67), SAM: 303.26 (-0.97), AAPL: 127.08 (+0.62), UNP: 122.60 (-1.23), CL: 70.08 (+0.23)
Delisting of Securities of GT Advanced Technologies, Inc., Dendreon Corporation, MabVax Therapeutics Holdings, Inc., and Tri-Tech Holding Inc. From The Nasdaq Stock Market
GlobeNewswire - Wed Dec 10, 3:05PM CST
The Nasdaq Stock Market announced today that it will delist the common stock of GT Advanced Technologies, Inc. GT Advanced Technologies, Inc.'s stock was suspended on October 16, 2014 and has not traded on Nasdaq since that time.
NDAQ: 49.48 (-0.27)
Could This Company Follow in Dendreon's Footsteps?
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 10:11AM CST
When it comes to the investing world, the ultimate compliment you or your company can get is being compared to the likes of visionaries like Warren Buffett or iconic companies likes Apple or Coca-Cola . If there's an antithesis to the iconic...
KO: 41.99 (-0.18), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02), AAPL: 127.08 (+0.62)
A New Combined Approach to Cancer Immunotherapy is Needed
ACCESSWIRE - Mon Dec 01, 11:35AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / With the recent bankruptcy of Dendreon Corporation (NASDAQ
NDN) due to disappointing sales of its flagship Provenge prostate cancer vaccine, the future of cancer immunotherapy just got a bit cloudier. While Provenge itself will survive, Dendreon may end up going private in a debt restructuring deal. DNDN: 0.13 (-0.02), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
